General Information of Drug (ID: DMP2SGN)

Drug Name
Dabelotine Drug Info
Synonyms Dabelotine mesilate; S-12024; S-12024-2
Indication
Disease Entry ICD 11 Status REF
Cognitive impairment 6D71 Phase 3 [1]
Cross-matching ID
PubChem CID
177949
CAS Number
CAS 118976-38-8
TTD Drug ID
DMP2SGN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug(s) Targeting Adrenergic receptor (ADR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Celiprolol hcl DMD5LBX Hypertension BA00-BA04 Approved [3]
Ovine corticotropin-releasing hormone DME0F98 Cushing disease 5A70 Approved [4]
Befunolol hci DM8WCXM Glaucoma/ocular hypertension 9C61 Approved [3]
Oxilofrine DMRKOS1 Orthostatic hypotension BA21 Approved [4]
Terbutyline DMVPWLZ Hypertension BA00-BA04 Approved [4]
Guanadrel Sulfate DM6S157 Hypertension BA00-BA04 Approved [5]
AR08 DM93CTQ Attention deficit hyperactivity disorder 6A05.Z Phase 2 [6]
PMID30124346-Compound-60TABLE5 DM3QX0R Dyskinesia MB47.4 Patented [7]
Etilefrine DM67PWD Cardiovascular disease BA00-BE2Z Withdrawn from market [4]
AIR-Epinephrine DMGAERX Allergy 4A80-4A85 Discontinued in Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor (ADR) TTVIREA NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002175)
2 US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation.
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014 June; 9(6): 579-594.
7 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
8 Prostaglandin synthesis inhibitors reverse alpha-adrenergic inhibition of acute insulin response to glucose. Am J Physiol. 1980 Dec;239(6):E490-500.